Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Mycophenolic acid sodium is a potent uncompetitive inhibitor of inosine monophosphate dehydrogenase (IMPDH), exhibiting an EC50 of 0.24 μM. It has broad antiviral activity against RNA viruses, including influenza. Additionally, mycophenolic acid sodium possesses immunosuppressive properties and exerts antiangiogenic and antitumor effects [1][2].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 8-10 weeks | $ 2,140.00 | |
50 mg | 8-10 weeks | $ 2,785.00 | |
100 mg | 8-10 weeks | $ 3,520.00 |
Description | Mycophenolic acid sodium is a potent uncompetitive inhibitor of inosine monophosphate dehydrogenase (IMPDH), exhibiting an EC50 of 0.24 μM. It has broad antiviral activity against RNA viruses, including influenza. Additionally, mycophenolic acid sodium possesses immunosuppressive properties and exerts antiangiogenic and antitumor effects [1][2]. |
In vitro | Mycophenolic acid sodium has been demonstrated to possess antiviral properties against an array of RNA viruses, including influenza, dengue virus, Zika virus, rotavirus, CCHFV, and hantavirus [1]. It targets IMPDH, a crucial enzyme in guanosine nucleotides' de novo synthesis [2]. When tested at concentrations ranging from 0.01 to 1 μM over 72 hours, mycophenolic acid sodium displayed a selective inhibitory effect on the proliferation of endothelial cells and fibroblasts, with endothelial cells being more susceptible (IC 50 <500 nM) to its antimitotic effects [2]. In contrast, fibroblasts showed a higher tolerance (IC 50 <1 μM). Among human tumor cell lines tested, A549 non-small cell lung cancer and PC3 prostate cancer cells manifested moderate sensitivity (IC 50 >1 μM), whereas U87 glioblastoma cells were resistant to up to 1 μM of mycophenolic acid sodium treatment [2]. Furthermore, a dose-dependent modulation of HDAC2 and MYC (down-regulation) and NDRG1 (up-regulation) was observed with mycophenolic acid sodium treatment (0.05-2 μM; 18 hours) [2]. In cell proliferation assays, primary isolated human dermal microvascular endothelial cells and fibroblasts were preferentially inhibited by the treatment, contrasting with U87 glioblastoma cells' resistance and the intermediate sensitivity of A549 and PC3 cancer cells [2]. Western Blot analysis further confirmed the dose-dependent regulatory effect of mycophenolic acid sodium on HDAC2, MYC, and NDRG1 in human dermal microvascular endothelial cells, providing a detailed understanding of its mechanism [2]. |
In vivo | Mycophenolic acid (120 mg/kg; oral gavage; b.i.d.) demonstrates potent anti-tumor activity by modifying the tumor microenvironment, significantly inhibiting the growth of U87 tumors in BALB/c nude mice [2]. Employing an animal model involving athymic 8-week-old, 20 g BALB/c nu/nu mice with a Mycophenolic acid-resistant human U87 tumor, a dosage of 120 mg/kg MMF (the morpholinoethyl ester prodrug of Mycophenolic acid) was administered orally twice a day. The results showed a remarkable reduction in tumor growth by approximately 70% 14 days post-tumor implantation in the MMF-treated group compared to controls. Additionally, MMF treatment resulted in a significant decrease in microvessel density (as indicated by CD31 staining) and pericyte coverage (assessed by α-smooth muscle actin staining) in tumors, with reductions of 44% and 78%, respectively, suggesting impaired tumor vascularization and highlighting its efficacy in combatting tumor proliferation [2]. |
Molecular Weight | 342.323 |
Formula | C17H19NaO6 |
CAS No. | 37415-62-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Mycophenolic acid sodium 37415-62-6 inhibitor inhibit